Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-21-011915
Filing Date
2021-06-09
Accepted
2021-06-09 21:41:46
Documents
2
Period of Report
2021-06-09

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_162328929258193.html 3  
1 FORM 3 wf-form3_162328929258193.xml 3 3333
2 MELISSA EPPERLY POA ex-24.htm EX-24 2164
  Complete submission text file 0001628280-21-011915.txt   6982
Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Epperly Melissa B, (Reporting) CIK: 0001807359 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39434 | Film No.: 211006731

Mailing Address 425 PONTIUS AVE N, STE 202 SEATTLE WA 98109
Business Address 425 PONTIUS AVE N, STE 202 SEATTLE WA 98109 206-333-2001
Nautilus Biotechnology, Inc. (Issuer) CIK: 0001808805 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 6770 Blank Checks